Cue Biopharma announces $12M public offering for research on novel biologics.

Cue Biopharma has announced a $12 million underwritten public offering of its common stock, which includes approximately 11.56 million shares and warrants for 2.89 million shares. Additionally, pre-funded warrants for nearly 12.44 million shares will be offered. This financing aims to support its research on novel biologics that target disease-specific T cells using their Immuno-STAT™ platform. The offering is expected to close around September 30, 2024.

September 26, 2024
10 Articles